HCPCS Level II · Drugs administered other than oral method
J9258Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
Terminated 09/30/2024
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9258
J9258 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg.
It was added to HCPCS effective 01/01/2024, and its current record took effect 10/01/2024.
It was terminated on 09/30/2024 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Paclitaxel (teva)
- Date added
- 01/01/2024
- Action effective
- 10/01/2024
- Termination date
- 09/30/2024
- BETOS
- O1D
Related J92xx codes
- J9200Injection, floxuridine, 500 mg
- J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202Goserelin acetate implant, per 3.6 mg
- J9203Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204Injection, mogamulizumab-kpkc, 1 mg
- J9205Injection, irinotecan liposome, 1 mg
- J9206Injection, irinotecan, 20 mg
- J9207Injection, ixabepilone, 1 mg
- J9208Injection, ifosfamide, 1 gram
- J9209Injection, mesna, 200 mg
- J9210Injection, emapalumab-lzsg, 1 mg
- J9211Injection, idarubicin hydrochloride, 5 mg
Common questions about J9258
Is HCPCS J9258 still valid?
- No. J9258 was terminated on 09/30/2024.
Does Medicare cover J9258?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.